Compare BFRI & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BFRI | HIND |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | United States | United States |
| Employees | 94 | 18 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 15.2M |
| IPO Year | N/A | 2016 |
| Metric | BFRI | HIND |
|---|---|---|
| Price | $1.19 | $2.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.75 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 393.6K | 10.8K |
| Earning Date | 05-13-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.36 | N/A |
| Revenue Next Year | $16.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $1.75 |
| 52 Week High | $1.27 | $12.87 |
| Indicator | BFRI | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 61.55 | 39.46 |
| Support Level | $0.71 | $1.78 |
| Resistance Level | N/A | $2.33 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 74.55 | 0.00 |
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.